Related Experiment Video

Updated: Apr 25, 2026

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

778

Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol

Lea Solman1, Amera Murabit2, Maria Gnarra1

  • 1Department of Dermatology, Great Ormond Street Hospital for Children, London, UK.

Archives of Disease in Childhood
|August 16, 2014
PubMed

Insights

Systemic propranolol is a safe and effective treatment for complicated infantile haemangiomas, showing good to excellent responses in 96% of patients. Adverse effects were manageable, with minimal regrowth observed after treatment cessation.

Area of Science:

  • Pediatric Dermatology
  • Vascular Anomalies
  • Pharmacology

Background:

  • Infantile haemangiomas are common benign vascular tumors in infants.
  • Complicated infantile haemangiomas can lead to significant morbidity, including vision compromise, bleeding, and airway obstruction.
  • Systemic propranolol has emerged as a potential therapeutic agent.

Purpose of the Study:

  • To evaluate the safety and efficacy of systemic propranolol for treating complicated infantile haemangiomas.
  • To determine response rates and identify adverse events associated with propranolol therapy.

Main Methods:

  • Retrospective review of medical records of pediatric patients treated with propranolol.
  • Inclusion criteria: complicated infantile haemangiomas, treatment duration of at least 3 months.
  • Data collected on patient demographics, indications for treatment, treatment duration, response, and adverse effects.

Main Results:

  • 250 patients received propranolol; common indications included vision compromise (42.0%) and bleeding/ulceration (30.4%).
  • 96% of patients showed a good to excellent response to treatment.
  • Adverse effects occurred in 15.2% of patients, with 10.4% requiring management modifications. Regrowth was observed in 8% upon cessation.

Conclusions:

  • Systemic propranolol is a safe and effective treatment option for selected patients with complicated infantile haemangiomas.
  • The benefits of propranolol therapy outweigh the risks in appropriately selected pediatric patients.
  • Continued monitoring is recommended due to potential for regrowth after treatment cessation.
Abstract

Keywords:
DermatologyGeneral Paediatrics

More Related Videos

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

15.0K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
511